Open Access

Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer

  • Authors:
    • Xiaoxiang Jie
    • Ming Du
    • Meng Zhang
    • Xiayu Jin
    • Qingqing Cai
    • Congjian Xu
    • Xiaoyan Zhang
  • View Affiliations

  • Published online on: June 30, 2022     https://doi.org/10.3892/etm.2022.11479
  • Article Number: 542
  • Copyright: © Jie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Circulating tumor DNA (ctDNA) is one conventional type of liquid biopsy that can be collected to dynamically monitor disease status. However, its potential clinical value and concordance with ascites samples or tumor biopsy needs to be evaluated further for patients with ovarian cancer. Therefore, the present study compared the mutation profiles among ctDNA, paired tumor tissue and ascites samples to explore their possible clinical value in ovarian cancer. Targeted next‑generation sequencing was used to screen for mutations in 18 peripheral blood samples, six paired ascites samples and eight paired tumor tissues collected from patients with ovarian cancer. Functional analyses were performed using public databases. WebGestalt was used to perform Gene Ontology and pathway enrichment analyses. The cBioPortal for Cancer Genomics was used to assess therapeutic targets. Chilibot and Search Tool for the Retrieval of Interacting Genes/Proteins were used to obtain key genes and their functional interactions. Comparative analysis was performed among the three types of samples using Venn diagram. A total of 104 cancer‑associated mutant genes in ctDNA samples, 95 genes in tumor tissues and 44 genes in ascites samples were found. A cluster covering 10 genes, namely NOTCH2, NOTCH3, lysine methyltransferase 2A, PTEN, androgen receptor, DNA‑activated protein kinase catalytic subunit, hepatocyte nuclear factor 1 homeobox A, SRC, insulin receptor substrate 2 and SRY‑box transcription factor 10, was obtained by Chilibot analysis. This gene panel may have the potential to monitor metastasis and identify therapeutic targets in ovarian cancer. Taken together, the present study focused on the mutant genes in ctDNA, ascites and tumor tissues, and suggested that the integrated information of different samples could be examined to comprehensively reflect the mutational landscape in ovarian cancer. However, procedures and protocols to interpret and utilize the integrated information obtained from various forms of liquid biopsies will require optimization prior to their use for future clinical applications.

Related Articles

Journal Cover

September-2022
Volume 24 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jie X, Du M, Zhang M, Jin X, Cai Q, Xu C and Zhang X: Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer. Exp Ther Med 24: 542, 2022
APA
Jie, X., Du, M., Zhang, M., Jin, X., Cai, Q., Xu, C., & Zhang, X. (2022). Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer. Experimental and Therapeutic Medicine, 24, 542. https://doi.org/10.3892/etm.2022.11479
MLA
Jie, X., Du, M., Zhang, M., Jin, X., Cai, Q., Xu, C., Zhang, X."Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer". Experimental and Therapeutic Medicine 24.3 (2022): 542.
Chicago
Jie, X., Du, M., Zhang, M., Jin, X., Cai, Q., Xu, C., Zhang, X."Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer". Experimental and Therapeutic Medicine 24, no. 3 (2022): 542. https://doi.org/10.3892/etm.2022.11479